Speaker Profile

Ph.D., MBA, CEO Colby Pharmaceutical Company

David Zarling PhD MBA is a Founder and the CEO of Colby Pharmaceutical Company (Menlo Park, California, www.colbypharma.com) and is leading the commercialization of IntraLymphNode Immunotherapeutics (CILNI™) and immunoactivating biological agents for cancer and other patients. David successfully managed the Colby team in the sale of three of their late pre-clinical or early clinical anti-cancer drugs and in Colby’s subsequent acquisition of Othera Pharmaceuticals with anti-inflammatory and anti-cancer clinical small molecule pharmaceutical drugs and drug candidates. David also successfully negotiated the world-wide exclusive license from MannKind Corporation to their immuno-therapeutics portfolio (including the technologies and products of CTL ImmunoTherapies and AlleCure Corporation), which are integral to the Colby immunotherapeutic and immunoactivating products.

Presentation Title and Company Description

Immunotherapy Showcase: Colby IntraLymphNode Immunotherapeutics (CILNI) & Immunoactivating Kirotopes™ For Cancer Patients’ Long-Term Durable Remissions

Colby and collaborators are clinically developing anti-inflammatory, -cancer and -autoimmune disease therapeutics. With clinical research professionals, we obtained human safety and efficacy in solid or hematological malignancies treated with proprietary cancer-specific targeted agents, using novel intralymphnode and other advanced delivery technologies resulting in significant long-term durable cancer patient remissions and potential cures. Our anti-inflammatory medicines are molecularly-targeted small molecule-, bio- and immuno-therapeutics advancing cost-effective clinical practices and favorable patient outcomes. Our molecularly targeted agents treat chronic inflammatory or hyper-proliferative diseases and are expanding clinical applications beyond cancer into targeted allergy, pain, regenerative and auto-immune medicines.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).